Oracle Runs

Will the results be positive?

Trial completed but no public readout of Part 2 efficacy (3-year EFS) available as of Apr 2026; est primary completion Mar 2026. Sources show Part 1 safety done, early MRD in descriptive cohort C with mixed negativity (44%), but no overall framing of trial as positive/negative. No sponsor press releases or topline on efficacy.

Will the results be positive?

Primary endpoint is 3-year EFS in Part 2 (CRLF2-rearranged Ph-like ALL cohort). No sources report mature EFS results, positive/negative framing, or clear efficacy success/failure for this exact trial. Available data limited to Part 1 safety, early MRD in non-CRLF2 Cohort C (mixed, marked decrement noted but undefined benefit), and ongoing status updates. Primary completion ~2026; full readout pending.

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Will the results be positive?

Public evidence does not show a clear Phase 2 efficacy readout. The cited trial-specific abstract reports only Part 1 safety/tolerability and says findings support continued efficacy evaluation in Part 2. A later review likewise says the study has thus far shown safety/tolerability only, not a clearly positive or negative outcome.

Will the results be positive?

No clear overall Phase 2 efficacy readout is public for NCT02723994. The cited trial-specific abstract reports only Part 1 safety/tolerability and says efficacy should be investigated in Part 2; FDA labeling also says safety/effectiveness in ALL were assessed but not established; tracker data indicate no posted results yet.